GlassScriptPhysician profile
Debra A Lusty
NPI 1477551067
$7,434.21
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $1,141 · 2021: $1,629 · 2022: $1,536 · 2023: $1,572 · 2024: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $829.46 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $739.55 | 2021-2024 | |
| Novo Nordisk INC | $727.33 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $560.12 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $543.97 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $528.62 | 2019-2024 | |
| Glaxosmithkline, LLC. | $414.30 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $322.57 | 2022-2024 | Rexulti |
| Amgen INC. | $226.38 | 2019-2024 | Evenity, Prolia |
| Allergan, INC. | $225.22 | 2019-2020 | |
| Astellas Pharma US INC | $224.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $199.00 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.52 | 2019-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.02 | 2022-2024 | Caplyta |
| Amarin Pharma, INC. | $147.23 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Lusty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.